论文部分内容阅读
目的评价金龙胶囊改善肝癌介入患者生存质量的临床疗效。方法 54例原发性肝癌患者共分为2组,观察组经肝动脉灌注栓塞治疗,另加金龙胶囊每日3次,每次3粒,术后第3天起服用。对照组除不用金龙胶囊外,其他治疗措施均与治疗组相同。结果观察组有效率为53.84%,对照组有效率为42.86%,两者比较有显著性差异(P>0.05)。结论金龙胶囊具有稳定瘤体,抑制肿瘤发展,提高生存质量,改善症状,减轻化疗药物的血液学毒性等作用,与化疗合用有相加、协同作用,不失为一种肝癌介入化疗栓塞的增效减毒剂。
Objective To evaluate the clinical efficacy of Jinlong Capsule in improving the quality of life of patients with liver cancer intervention. Methods 54 primary hepatocellular carcinoma patients were divided into two groups. The observation group was treated with hepatic arterial infusion and embolization. Plus Jinlong capsule was given 3 times a day for 3 capsules and taken on the 3rd day after operation. In addition to the control group without Jinlong capsule, the other treatment measures are the same with the treatment group. Results The effective rate of the observation group was 53.84%, while that of the control group was 42.86%. There was a significant difference between the two groups (P> 0.05). Conclusion Jinlong Capsule can stabilize the tumor, inhibit tumor development, improve quality of life, improve symptoms and reduce the hematological toxicity of chemotherapy drugs. It has the effect of adding and cooperating with chemotherapy, which is a synergistic effect of interventional chemoembolization Poison.